The long, tortuous race to market a therapeutic based on RNA interference (RNAi) may be nearing its end. Ken Garber reports.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Garber, K. Nat. Biotechnol. 34, 1213–1214 (2016)
Elbashir, S.M. et al. Nature 411, 494–498 (2001).
Zuckerman, J.E. et al. Proc. Natl. Acad. Sci. USA 111, 11449–11454 (2014).
Tabernero, J. et al. Cancer Discov. 3, 406–417 (2013).
Coelho, T. et al. N. Engl. J. Med. 369, 819–829 (2013).
Nair, J.K. et al. J. Am. Chem. Soc. 136, 16958–16961 (2014).
Fitzgerald, K. et al. N. Engl. J. Med. 376, 41–51 (2017).
Grimm, D. et al. Nature 441, 537–541 (2006).
Shen, W., Liang, X.H., Sun, H. & Crooke, S.T. Nucleic Acids Res. 43, 4569–4578 (2015).
Janas, M.M. et al. Nucleic Acids Ther. doi:1089/nat.2016.0639 (2016).
Pasi K.J. et al. Blood 128, 1397 (2016).
Ragni, M.V. Blood 128, 2572 (2016).
Sardh, E. et al. Blood 128, 2318 (2016).
Meade, B.R. et al. Nat. Biotechnol. 32, 1256–1261 (2014).
Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A. & Davis, M.E. Proc. Natl. Acad. Sci. USA 104, 15549–15554 (2007).
Semple, S.C. et al. Nat. Biotechnol. 28, 172–176 (2010).
Judge, A. & MacLachlan, I. Hum. Gene Ther. 19, 111–124 (2008).
Barros, S.A. & Gollob, J.A. Adv. Drug Deliv. Rev. 64, 1730–1737 (2012).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Worth the RISC?. Nat Biotechnol 35, 198–202 (2017). https://doi.org/10.1038/nbt.3810
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3810
This article is cited by
-
Tapping the RNA world for therapeutics
Nature Structural & Molecular Biology (2018)
-
With Alnylam's amyloidosis success, RNAi approval hopes soar
Nature Biotechnology (2017)